Browse > Article
http://dx.doi.org/10.4014/jmb.1106.06021

Improved Immune Response to Recombinant Influenza Nucleoprotein Formulated with ISCOMATRIX  

Cargnelutti, Diego E. (Institute of Experimental Medicine and Biology of Cuyo (IMBECU- CONICET))
Sanchez, Maria V. (Institute of Experimental Medicine and Biology of Cuyo (IMBECU- CONICET))
Alvarez, Paula (Animal Virology Center, Institute of Science and Technology Dr. Cesar Milstein, CONICET)
Boado, Lorena (Animal Virology Center, Institute of Science and Technology Dr. Cesar Milstein, CONICET)
Glikmann, Graciela (Virology Laboratory, Department of Science and Technology, National University of Quilmes)
Mattion, Nora (Animal Virology Center, Institute of Science and Technology Dr. Cesar Milstein, CONICET)
Scodeller, Eduardo A. (Institute of Experimental Medicine and Biology of Cuyo (IMBECU- CONICET))
Publication Information
Journal of Microbiology and Biotechnology / v.22, no.3, 2012 , pp. 416-421 More about this Journal
Abstract
Current influenza vaccines elicit antibodies effective against homologous strains, but new strategies are urgently needed for protection against emerging epidemic or pandemic strains. Although influenza vaccine candidates based on the viral nucleoprotein (NP) or matrix protein do not elicit sterilizing immunity, they have the advantage of inducing immunity that may cover a larger number of viral strains. In this study, recombinant NP produced in Escherichia coli was purified and formulated in combination with the adjuvant ISCOMATRIX. This formulation increased a NP-specific immunity in mice, with a Th1 profile, and may constitute a promising low-cost influenza vaccine candidate, with ability to stimulate humoral and cellular immune responses.
Keywords
Influenza; recombinant nucleoprotein; ISCOMATRIX;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 LaMere, M. W., H. T. Lam, A. Moquin, L. Haynes, F. E. Lund, T. D. Randall, and D. A. Kaminski. 2011. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186: 4331-4339.   DOI   ScienceOn
2 LaMere, M. W., A. Moquin, F. E. Lee, R. S. Misra, P. J. Blair, L. Haynes, et al. 2011. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 85: 5027-5035.   DOI   ScienceOn
3 Leroux-Roels, I., F. Roman, S. Forgus, C. Maes, F. De Boever, M. Dramé, et al. 2010. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a doubleblind randomised primary study. Vaccine 28: 849-857.   DOI   ScienceOn
4 Loudon, P. T., E. J. Yager, D. T. Lynch, A. Narendran, C. Stagnar, A. M. Franchini, et al. 2010. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 5: e11021.   DOI   ScienceOn
5 McKenzie, A., M. Watt, and C. Gittleson. 2010. ISCOMATRIX(R) vaccines: Safety in human clinical studies. Hum. Vaccin 30: 6(3).
6 Pearse, M. J. and D. Drane. 2005. ISCOMATRIX(R) adjuvant for antigen delivery. Adv. Drug Deliv. Rev. 57: 465-474.   DOI   ScienceOn
7 Pertmer, T. M., M. D. Eisenbraun, D. McCabe, S. K Prayaga, D. H. Fuller, and J. R. Haynes. 1995. Gene gun-based nucleic acid immunization: Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13: 1427-1430.   DOI   ScienceOn
8 Prabakaran, M., S. Madhan, N. Prabhu, J. Qiang, and J. Kwang. 2010. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J. Virol. 84: 3201-3209.   DOI   ScienceOn
9 Price, G. E., M. R. Soboleski, C. Y. Lo, J. A. Misplon, M. R. Quirion, K. V. Houser, et al. 2010. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5: e13162.   DOI   ScienceOn
10 Quan, F. S., R. W. Compans, H. H. Nguyen, and S. M. Kang. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82: 1350-1359.   DOI   ScienceOn
11 Rao, S. S., W. P. Kong, C. J. Wei, N. Van Hoeven, J. P. Gorres, M. Nason, et al. 2010. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 5: e9812.   DOI   ScienceOn
12 Scheepers, K. and H. Becht. 1994. Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes. Med. Microbiol. Immunol. 183: 265-278.   DOI   ScienceOn
13 Schwartz, J. A., L. Buonocore, A. Suguitan Jr, M. Hunter, P. A. Marx, K. Subbarao, et al. 2010. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J. Virol. 84: 4611-4618.   DOI   ScienceOn
14 Steitz, J., P. G. Barlow, J. Hossain, E. Kim, K. Okada, T. Kenniston, et al. 2010. A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS One 5: e10492.   DOI   ScienceOn
15 Tamura, S. 2010. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine 28: 6393-6397.   DOI   ScienceOn
16 Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.   DOI
17 Thueng-in, K., S. Maneewatch, P. Srimanote, T. Songserm, P. Tapchaisri, N. Sookrung, et al. 2010. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines. Vaccine 28: 6765-6777.   DOI   ScienceOn
18 Tite, J. P., S. M. Russell, G. Dougan, D. O'Callaghan, I. Jones, G. Brownlee, and F. Y. Liew. 1998. Antiviral immunity induced by recombinant nucleoprotein of influenza A virus. I. Characteristics and cross-reactivity of T cell responses. J. Immunol. 141: 3980-3987.
19 Tite, J. P., C. Hughes-Jenkins, D. O'Callaghan, G. Dougan, S. M. Russell, X. M. Gao, and F. Y. Liew. 1990. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology 71: 202-207.
20 Windon, R. G., P. J. Chaplin, P. McWaters, M. Tavarnesi, M. Tzatzaris, W. G. Kimpton, et al. 2001. Local immune responses to influenza antigen are synergistically enhanced by the adjuvant ISCOMATRIX. Vaccine 20: 490-497.   DOI   ScienceOn
21 Wraith, D. C. and B. A. Askonas. 1985. Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation. J. Gen. Virol. 66: 1327-1331.   DOI   ScienceOn
22 Wraith, D. C., A. E. Vessey, and B. A Askonas. 1987. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 68: 433-440.   DOI   ScienceOn
23 Durando, P., R. Iudici, C. Alicino, M. Alberti, D. D. Florentiis, F. Ansaldi, and G. Icardi. 2011. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum. Vaccin. 7: 1-2.
24 Yewdell, J. W., J. R. Bennink, G. L Smith, and B. Moss. 1985. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 82: 1785-1789.   DOI   ScienceOn
25 Zhou, D., T. L. Wu, M. O. Lasaro, B. P. Latimer, E. M. Parzych, A. Bian, et al. 2010. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol. Ther. 18: 2182-2189.   DOI   ScienceOn
26 Berthoud, T. K., M. Hamill, P. J. Lillie, L. Hwenda, K. A. Collins, K. J. Ewer, et al. 2011. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVANP+M1. Clin. Infect. Dis. 52: 1-7.   DOI   ScienceOn
27 Coffman, R. L., B. W. Seymour, D. A Lebman, D. D Hiraki, J. A Christiansen, B. Shrader, et al. 1998. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102: 5-28.
28 Dormitzer, P. R., G. Galli, F. Castellino, H. Golding, S. Khurana, G. Del Giudice, and R. Rappuoli. 2011. Influenza vaccine immunology. Immunol. Rev. 239: 167-177.   DOI   ScienceOn
29 Ebrahimi, S. M., M. Tebianian, K. Aghaiypour, H. Nili, and A. Mirjalili. 2010. Prokaryotic expression and characterization of avian influenza A virus M2 gene as a candidate for universal recombinant vaccine against influenza A subtypes; specially H5N1 and H9N2. Mol. Biol. Rep. 37: 2909-2914.   DOI   ScienceOn
30 Furuya, Y., M. Regner, M. Lobigs, A. Koskinen, A. Mullbacher, and M. Alsharifi. 2010. Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations. J. Gen. Virol. 91: 1450-1460.   DOI   ScienceOn
31 Guo, L., M. Zheng, Y. Ding, D. Li, Z. Yang, H. Wang, et al. 2010. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch. Virol. 155: 1765-1775.   DOI   ScienceOn
32 Khurana, S., W. Chearwae, F. Castellino, J. Manischewitz, L. R. King, A. Honorkiewicz, et al. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2: 15ra5.   DOI   ScienceOn
33 Hessel, A., M. Schwendinger, D. Fritz, S. Coulibaly, G. W. Holzer, N. Sabarth, et al. 2010. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS One 5: e12217.   DOI
34 Hurwitz, J. L., C. J. Hackett, E. C. McAndrew, and W. Gerhard. 1985. Murine TH response to influenza virus: Recognition of hemagglutinin, neuraminidase, matrix, and nucleoproteins. J. Immunol. 134: 1994-1998.
35 Jelinek, I., J. N. Leonard, G. E. Price, K. N. Brown, A. Meyer-Manlapat, P. K Goldsmith, et al. 2011. TLR3-specific doublestranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 186: 2422-2429.   DOI   ScienceOn
36 Kistner, O., B. A. Crowe, W. Wodal, A. Kerschbaum, H. Savidis-Dacho, N. Sabarth, et al. 2010. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 5: e9349.   DOI   ScienceOn
37 Kreijtz, J. H., Y. Suzer, R. Bodewes, A. Schwantes, G. van Amerongen, R. J. Verburgh, et al. 2010. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J. Gen. Virol. 91: 2745-2752.   DOI   ScienceOn
38 Laddy, D. J., J. Yan, A. S. Khan, H. Andersen, A. Cohn, J. Greenhouse, et al. 2009. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 83: 4624-4630.   DOI   ScienceOn